Latest Headlines

Latest Headlines

Crucell wins $70M to develop new vaccines

Crucell has nailed a $70 million contract from the National Institutes of Allergy and Infectious Diseases to develop new vaccines to combat the Ebola and Marburg viruses. That contract will be worth

Developers tout protein manufacturing breakthrough

A joint venture between Crucell and DSM Biologics- Percivia-- has produced a new, more efficient approach to manufacturing monoclonal antibodies and proteins. By relying on human cell lines rather

Crucell reports early-stage success with TB vaccine

Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is

In surprise move, Crucell dumps West Nile program

The Dutch developer Crucell has opted to shelve its development program for a West Nile vaccine after seeing a drop in the number of people infected by the virus in the U.S. That was a surprise move

ALSO NOTED: iCardiac gains venture funds; Sirtris reports rising R&D expenses; Nanogen slashes staff; and much more...

> iCardiac Technologies, which has advanced new technology to assess drug safety, has announced a second round of venture capital but is staying mum about just how much money it is getting.

ALSO NOTED: NicOx posts positive osteoarthritis data; Genzyme snares diagnostics unit; Infinity regains program rights; and muc

> France's NicOx has posted positive data from a late-stage study of naproxcinod for osteoarthritis.

Sanofi launches trial of revolutionary flu vaccine

Sanofi-Aventis has launched a mid-stage study of a new seasonal flu vaccine that hopes to advance a completely new method to make vaccines. The vaccine is made from cell cultures as opposed to the

SPOTLIGHT: Crucell, MedImmune strike deal

Dutch biotech Crucell has inked a joint venture deal with MedImmune to develop its bacterial antibodies to treat hospital-acquired infections. MedImmune has agreed to provide upfront, annual and

ALSO NOTED: Crucell disavows trial failure; Emisphere agrees to $18M settlement; Elusys wins $12M contract; and much more...

> Crucell says you shouldn't blame its technology for the failure of Merck's

Press Release: Crucell N.V. Announces STAR(TM) Research License Agreement With Novo Nordisk

Press Release: Crucell N.V. Announces STAR(TM) Research License Agreement With Novo Nordisk